| 4.860% |
| 0.00% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 3.7M | $5.2M | +18.1% | 3.011% | 0.00% |
| 5 | Samsara BioCapital, LLC | 3.4M | $4.8M | 0.0% | 2.801% | 0.39% |
| 6 | Kohlberg Kravis Roberts & Co. L.P. | 3.0M | $4.2M | 0.0% | 2.480% | 0.07% |
| 7 | STATE STREET CORP | 2.4M | $3.3M | +2.4% | 1.946% | 0.00% |
| 8 | TWO SIGMA INVESTMENTS, LP | 2.3M | $3.2M | -1.8% | 1.846% | 0.00% |
| 9 | CM Management, LLC | 2.1M | $2.9M | 0.0% | 1.716% | 1.87% |
| 10 | Alyeska Investment Group, L.P. | 1.7M | $2.4M | -23.0% | 1.416% | 0.01% |
| 11 | Hudson Bay Capital Management LP | 1.7M | $2.4M | -0.7% | 1.383% | 0.01% |
| 12 | AQR CAPITAL MANAGEMENT LLC | 1.3M | $1.9M | +10.3% | 1.087% | 0.00% |
| 13 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 1.2M | $1.7M | +6.2% | 1.003% | 0.00% |
| 14 | PANAGORA ASSET MANAGEMENT INC | 1.1M | $1.6M | -22.1% | 0.929% | 0.00% |
| 15 | NORTHERN TRUST CORP | 1.1M | $1.6M | +23.6% | 0.923% | 0.00% |
| 16 | VANGUARD FIDUCIARY TRUST CO | 1.0M | $1.4M | +7.0% | 0.830% | 0.00% |
| 17 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 900K | $1.3M | 0.0% | 0.735% | 0.00% |
| 18 | VANGUARD PORTFOLIO MANAGEMENT LLC | 883K | $1.2M | +46.1% | 0.722% | 0.00% |
| 19 | UBS Group AG | 760K | $1.1M | +39.0% | 0.621% | 0.00% |
| 20 | GOLDMAN SACHS GROUP INC | 602K | $843K | -13.5% | 0.492% | 0.00% |
| 21 | RENAISSANCE TECHNOLOGIES LLC | 563K | $788K | +69.8% | 0.460% | 0.00% |
| 22 | STRS OHIO | 396K | $554K | +22.1% | 0.323% | 0.00% |
| 23 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | 391K | $547K | -11.3% | 0.319% | 0.01% |
| 24 | Invesco Ltd. | 354K | $495K | +5.5% | 0.289% | 0.00% |
| 25 | Bank of New York Mellon Corp | 320K | $448K | +12.2% | 0.261% | 0.00% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in CHRS — a direct measure of their conviction.
| 67.67% |
| 5.63 pp |
| $48M |
| 46% |
| Q4 2024 | 123 | 3.9% | 73.30% | 126.69 pp | $89M | 72% |
| Q3 2024 | 128 | — | 199.99% | — | $313M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
9 institutions opened new positions in CHRS during Q2 2026, while 20 fully exited. 34 added to existing positions and 101 trimmed.
CHRS institutional ownership rose by 8.95 percentage points quarter-over-quarter, with a net change of -10 holders.
The top 10 institutions account for 73.1% of all reported 13F value in CHRS, and the top 25 account for 91.8%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Coherus Oncology, Inc. (CHRS) Institutional Ownership